截骨矫形"∩"形钉内固定治疗关节畸形55例

目的探讨肘、膝、踝关节内外翻畸形的治疗方式。方法对55例8～16岁的关节内、外翻畸形患儿(肘关节30例，膝15例，踝10例)，采用肘外侧切口，踝、膝内外侧切口，截骨矫形，1枚或2枚“∩”形钉内崮定治疗，术后石膏托外固定4周，结果随访50例，随访时间3～24个月，截骨均达到骨性愈合，无一例发生感染，内固定松动临床疗效优48例(96％)，良2例(4％)。结论用“∩”形钉作为截骨矫形内固定材料．具有操作简单、损伤小、效果好的优点。     

Quantitative relationship between pupillary reflex feature and its diopter in retinoscopy

ＱｕａｎｔｉｔａｔｉｖｅｒｅｌａｔｉｏｎｓｈｉｐｂｅｔｗｅｅｎｐｕｐｉｌｌａｒｙｒｅｆｌｅｘｆｅａｔｕｒｅａｎｄｉｔｓｄｉｏｐｔｅｒｉｎｒｅｔｉｎｏｓｃｏｐｙＸｕＳｈａｎｇ（徐上）；ＪｉＳｈａｎｇｎｉａｎ（计尚年）（ＤｅｐａｒｔｍｅｎｔｏｆＯｐｈｔｈ...     

Reversal of fulminant hepatic failure using an extracorporeal liver assist device.

Liver transplantation is currently the only effective therapy for patients with fulminant hepatic failure. The availability of an artificial liver could bridge these patients through the relatively brief crisis period and allow their own livers to regenerate, providing a more favorable outcome and sparing the trauma and expense of transplant. We have developed a device consisting of a highly differentiated human liver cell line cultured in a hollow fiber cartridge. This device is capable of supporting dogs with acetaminophen-induced fulminant hepatic failure for a period long enough for their own livers to resume function. Even though liver function tests such as albumin and prothrombin time became extremely abnormal during the course of the experiment, the dogs did not become encephalopathic. Two of the three treated animals recovered sufficient liver function after 42 to 48 hr of treatment that they could be disconnected from the device, and they survived the experiment. Histological results and serum ALT levels suggest that the device affected the course of the disease in two animals, allowing recovery of hepatocytes that would otherwise have lysed. In the third animal, regenerative nodules demonstrated that, even in the presence of severe liver injury, the device was capable of supporting total liver function.     

Diffusion‐Weighted MRI in Creutzfeldt‐Jakob Disease: A Better Diagnostic Marker Than CSF Protein 14‐3‐3?

Two middle-aged patients presented with rapidly progressive dementia and ataxia, nonspecific electroencephalography findings, and negative cerebrospinal fluid (CSF) protein 14-3-3. Both patients underwent brain magnetic resonance imaging (MRI) scans that demonstrated abnormalities on diffusion-weighted imaging (DWI) sequences, and both were later confirmed to have Creutzfeldt-Jakob disease. (CJD) by tissue examination. Because a recent position paper from the American Academy of Neurology characterized CSF protein 14-3-3 as a gold standard for clinically diagnosing CJD, the authors reviewed studies of CJD in which DWI-MRI imaging and CSF protein 14-3-3 studies were both performed. Among 19 reported cases of CJD with DWI-MRI lesions, CSF protein 14-3-3 was negative in 6 cases and positive in 2 others. The authors' findings suggest that multifocal cortical and subcortical hyperintensities confined to gray matter regions in DWI-MRI may be a more useful noninvasive diagnostic marker for CJD than CSF protein 14-3-3. These observations provide a compelling rationale for a prospective comparative study.     

The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.

BACKGROUND AND PURPOSE: The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-dose rate (LDR) studies, with an estimated loss of local control ranging from 0.3 to 1.6% per day of treatment prolongation. Since the treatment schedule for fractionated high-dose rate intracavitary brachytherapy (HDRICB) is not directly comparable with that for low-dose rate studies, this report aims to evaluate the adverse effect of treatment prolongation specifically for cervical cancer treated with HDRICB. MATERIAL AND METHODS: From September 1992 to December 1997, 257 patients diagnosed with uterine cervical cancer (35 Ib, 26 IIa, 122 IIb, 10 IIIa, 57 IIIb, 7 IVa), who underwent external radiotherapy combined with between two and four courses of HDRICB and a minimum of 3 years of follow-up (median 57 months), were analyzed. Treatment consisted of irradiation of the whole pelvis with 44-45 Gy consisting of 22-25 fractions by 5 weeks, with the dose boosted to 54-58 Gy (with central shielding) for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease. HDRICB was performed using an Ir-192 remote afterloading technique at 1-week intervals. The standard prescribed dose for each course of HDRICB was 7.2 Gy to point A for three insertions (before July 1995), or 6.0 Gy to point A for four insertions (after July 1995). Total prescribed point A doses (external beam radiotherapy+HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while analogous dosage for larger lesions (stage IIb-IVa) ranged from 59 to 75.6 Gy (median, 65.6 Gy). Kaplan-Meier and multivariate analyses were used to test the effect of treatment time on pelvic control rate (PCR) and cause-specific survival (CSS) at 5 years. RESULTS: Median treatment time was 63 days. For all stages of disease, the 5-year CSS and PCR were significantly different comparing treatment times of less than and greater than or equal to 63 days [83% and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. These associations were also significant for stage Ib/IIa [97% and 79% (P=0.01), and 100% and 87% (P=0.02), respectively), but not for stage IIb [75% and 72% (P=0.79), and 93% and 87% (P=0.83), respectively] or stage III [66% and 49% (P=0.2), and 83% and 72% (P=0.21), respectively]. Multivariate analysis identified three prognostic factors for CSS, stage (P<0.001), tumor response to external RT (P=0.001), and overall treatment time (OTT; P=0.006). Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external RT (P=0.001), and OTT (P=0.03). Prolongation of treatment time resulted in a daily decrease in pelvic control rate of 0.67% overall, and 0.43% for stage Ib-IIa, 0.57% for stage IIb, and 0.73% for stage III patients. CONCLUSION: Analysis of the data from the current study demonstrates that the adverse effect of treatment prolongation was observed later in the treatment course for the high-dose rate (HDR) series compared to the LDR analog, however, treatment-time prolongation still negatively influenced the cause-specific survival and pelvic control rate for both dosage groups.     

Perforation of the large bowel during colonoscopy in Singapore

The management of seven patients with colonoscopy-related perforations is described. This study demonstrates the need for an early laparotomy. A high index of suspicion is required to reach an early diagnosis. Patients with no preexisting medical problems who underwent early surgery recovered with little morbidity. In elderly patients (greater than 75 years), colonoscopic perforation can be fatal. Endoscopy should be performed with special care in such patients.     

肝细胞癌上皮细胞白蛋白和CK7的表达

目的 探讨人类肝癌肝组织是否存在小上皮细胞（small epithelial cell,SEC),这类细胞是否表达白蛋白CK7抗体,对30例人肝细胞肝癌的手术标本材料作免疫组化染色,对其中10例作超微结构观察和白蛋白及CK7的免疫电镜标记。结果 30例中有20例在肝癌肿瘤边缘和增生的小胆管发现有少量SEC。这类细胞既表达白蛋白,又表达CK7。电镜下,这类SEC体积较小,核大,胞质少胞质内主要为游离核糖体,并有胞质内张力微丝及细胞间连接结构。免疫电镜下,10例中有5例可显示在同一SEC同时表达白蛋白和CK7。结论 人肝细胞癌肝中确实存在SEC。这类SEC具有与人肝母细胞瘤和胆道闭锁肝组织中的SEC一样的形态和免疫表型特点。     

奥曲肽治疗肝硬变食管静脉曲张破裂出血

0　引言　我院 1996 - 0 6 / 1998- 0 7用奥曲肽治疗肝硬变食管静脉曲张破裂出血 19例 ,并与垂体后叶素作了对照 .1　对象和方法1.1　对象　经内镜证实食管静脉曲张破裂出血 37例 ;男 32例 ,女 5例 ;年龄 42～ 6 9岁 .肝炎后肝硬变 32例 ,乙醇性肝硬变 3例 ,血吸虫性肝硬变 2例 .按就诊顺序随机分为治疗组19例 ,对照 18例 .估计出血量 :治疗组 (146 3.6± 375 .8) m L;对照组 (144 9.5± 36 8.4) m L .出血至治疗间隔时间 :治疗组(11.6± 3.5 ) h;对照组 (11.2± 3.6 ) h.两组的年龄、性别、肝功 Child分级、食管静脉曲张程度、出血量、出…